Clinical Trials Logo

Paranoia clinical trials

View clinical trials related to Paranoia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01028677 Active, not recruiting - Schizophrenia Clinical Trials

Oxytocin Treatment of Schizophrenia

OTS
Start date: November 2009
Phase: N/A
Study type: Interventional

Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia. Participants: 80 adults with schizophrenia for at least one year and with a high rating for paranoia. Procedures (methods): Oxytocin or placebo will be administered twice daily in an intranasal spray (6 insufflations/dose or 24 IU) for 6 weeks. Before, during and at the end of the trial, each subject will undergo psychiatric symptom ratings and tests of mental abilities used in social functioning and social competence and subjects and an informant will complete ratings of social functioning.